Therapeutic agent

Tirzepatide

PreliminaryEvidence level
1Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
GLP-1/GIP agonist early Long COVID trials (metabolic/anti-inflammatory). Weekly titrated injection. GI side effects, cost. May benefit overweight subsets. Very early.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT07128082The Long COVID Treatment TrialPhase 2Active, not recruiting

Key Studies / References

  • See linked studies